Evolving challenges in hepatic fibrosis (Q37768335)

22 August 2017

1 reference

title

Evolving challenges in hepatic fibrosis (English)

1 reference

22 August 2017

Scott L Friedman

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

29 June 2010

1 reference

Nature Reviews Gastroenterology & Hepatology

22 August 2017

published in

1 reference

22 August 2017

volume

7

1 reference

22 August 2017

issue

8

1 reference

22 August 2017

page(s)

425-436

1 reference

Epithelial-mesenchymal transition and its implications for fibrosis

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Sampling variability of liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Increased caffeine consumption is associated with reduced hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Institute of Medicine recommendations for the prevention and control of hepatitis B and C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

The global impact of hepatic fibrosis and end-stage liver disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Recent advances in nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Non-alcoholic steatohepatitis and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Primary liver cancers with nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

31 March 2020

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Mechanisms of hepatic fibrogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Liver fibrosis: cellular mechanisms of progression and resolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Fibrogenic potential of human multipotent mesenchymal stromal cells in injured liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Hematopoietic origin of hepatic stellate cells in the adult liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

The bone marrow functionally contributes to liver fibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Pathological roles of bone marrow-derived stellate cells in a mouse model of alcohol-induced fatty liver.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

New mechanisms of pulmonary fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Fibroblast activation and myofibroblast generation in obstructive nephropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Negligible contribution of bone marrow-derived cells to collagen production during hepatic fibrogenesis in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Epithelial-to-mesenchymal transitions in the liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

CD133+ hepatic stellate cells are progenitor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

The niche of stellate cells within rat liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Relationships among stellate cell activation, progenitor cells, and hepatic regeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

CCR2 promotes hepatic fibrosis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Cytokine receptors and signaling in hepatic stellate cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Adipokines in liver diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Role of adipocytokines in hepatic fibrogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Wound healing and local neuroendocrine regulation in the injured liver.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

p75 Neurotrophin receptor signaling regulates hepatic myofibroblast proliferation and apoptosis in recovery from rodent liver fibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Angiogenesis in liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Redox mechanisms in hepatic chronic wound healing and fibrogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

31 March 2020

NOX in liver fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

The role of matrix stiffness in regulating cell behavior

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

NK and NKT cells in liver injury and fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

TLR4 enhances TGF-beta signaling and hepatic fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Toll-like receptors and adaptor molecules in liver disease: update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Toll-like receptors as targets in chronic liver diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

NF-kappaB signalling: embracing complexity to achieve translation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Inflammasome-mediated regulation of hepatic stellate cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Transcriptional regulation of hepatic stellate cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

RNA-binding protein RBMS3 is expressed in activated hepatic stellate cells and liver fibrosis and increases expression of transcription factor Prx1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: An essential role for apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

A ribosomal S-6 kinase-mediated signal to C/EBP-beta is critical for the development of liver fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Reversal of hepatic fibrosis -- fact or fantasy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Inverse association between hepatic stellate cell apoptosis and fibrosis in chronic hepatitis C virus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Senescence of activated stellate cells limits liver fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Elastography for the non-invasive assessment of liver disease: limitations and future developments.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Acute viral hepatitis increases liver stiffness values measured by transient elastography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging--initial experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Functional magnetic resonance imaging monitoring of pathological changes in rodent livers during hyperoxia and hypercapnia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Acoustic radiation force impulse imaging of the abdomen: demonstration of feasibility and utility.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Review article: breath testing for human liver function assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

13C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Antifibrotic therapies--emerging biomarkers as treatment end points

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Role of host genetics in fibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Genetic determinants in hepatic fibrosis: from experimental models to fibrogenic gene signatures in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

CC chemokine receptor 5 delta32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

A novel nonsynonymous variant of matrix metalloproteinase-7 confers risk of liver cirrhosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Hepatitis B virus genotype C is associated with more severe liver fibrosis than genotype B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Fibrosis and cirrhosis reversibility: clinical features and implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

A microcholangiographic study of liver disease models in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Reversibility of hepatic fibrosis and cirrhosis--is it all hype?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Advances in antifibrotic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Current and future anti-fibrotic therapies for chronic liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

PDGF-receptor beta-targeted adenovirus redirects gene transfer from hepatocytes to activated stellate cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Targeting siRNA to arrest fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2010.97

The epithelial-to-mesenchymal transition in liver fibrosis: here today, gone tomorrow?

31 March 2020

1 reference

12 December 2020

In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha

1 reference

12 December 2020

Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats

1 reference

12 December 2020

Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans

1 reference

12 December 2020

CCR1 and CCR5 promote hepatic fibrosis in mice

1 reference

12 December 2020

Reversibility of liver fibrosis.

1 reference

12 December 2020

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRGASTRO.2010.97

1 reference

22 August 2017

1 reference